Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22552623 | 1.00 | MAPT (0.34) | MAPTABCC4TDP1ALDH1A1DDAH1 | |
| SCHEMBL1882682 | 0.83 | RNPEP (0.35) | MAPTALDH1A1FAAHUSP2CYP3A4 | |
| SCHEMBL1882200 | 0.83 | FAAH (0.37) | MAPTABCC4ALDH1A1DDAH1FAAH | |
| SCHEMBL15698565 | 0.80 | TSHR (0.39) | MAPTABCC4ALDH1A1DDAH1GRIK1 | |
| SCHEMBL629530 | 0.80 | TSHR (0.39) | MAPTABCC4ALDH1A1DDAH1GRIK1 | |
| SCHEMBL27696125 | 0.80 | TSHR (0.39) | MAPTABCC4ALDH1A1DDAH1GRIK1 | |
| SCHEMBL3116761 | 0.78 | SLC1A3 (0.42) | MAPTABCC4TDP1ALDH1A1DDAH1 | |
| SCHEMBL4539895 | 0.78 | TSHR (0.38) | MAPTABCC4ALDH1A1DDAH1GRIK1 | |
| SCHEMBL10967083 | 0.78 | ABCC4 (0.34) | MAPTABCC4TDP1ALDH1A1DDAH1 | |
| SCHEMBL6120459 | 0.78 | TSHR (0.38) | MAPTABCC4ALDH1A1DDAH1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3681875-A1 | CYCLIC PEPTIDE ANTIBIOTICS | H. Hoffnabb-La Roche Ag (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-111148739-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019052545-A1 | CYCLIC PEPTIDE ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | MAPT 4597/4885ABCC4 2709/4885TDP1 2506/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | MAPT 4597/4885ABCC4 2709/4885TDP1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.